Although PD‐1/PD‐L1 blockade has been approved in Non‐small cell lung cancer (NSCLC), some clinical trials have reported that NSCLC patients with EGFR mutations do not benefit from this therapy and that it may even lead to a more rapid disease progression.1, 7, 25 Therefore, we compared the median TMB of LUAD patients with mutant (n = 77) and wild‐type (n = 99) EGFR genes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.